Last10K.com

Centaur Guernsey L.P. Inc. (1557939) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Acelity L.P. Inc.

CIK: 1557939


         

FOR MORE INFORMATION, CONTACT:
Investors

News Media
Nathan Speicher
Mike Barger
Office: (210) 255-6027
Office: (210) 255-6824
nathan.speicher@kci1.com
mike.barger@kci1.com

CENTAUR GUERNSEY L.P. INC. REPORTS
FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS FOR 2013


-  Fourth quarter 2013 Centaur Guernsey L.P. Inc. (“Centaur” or the "Company") revenue of $469.8 million, up 6.8% from the prior-year period as reported and 7.3% from the prior-year period on a constant currency basis

- Fourth quarter 2013 loss from continuing operations of $51.7 million compared to $56.2 million for the prior-year period

-  Fourth quarter 2013 total Adjusted EBITDA from continuing operations1 of $191.9 million compared to $193.0 million for the prior-year period

- KCI closed on the previously-announced acquisition of SystagenixTM


Highlights of the fourth quarter and year ended December 31, 2013

Centaur revenue for the fourth quarter of 2013 was $469.8 million, up from the prior-year comparable period by 7.3% on a constant currency basis. Our loss from continuing operations for the fourth quarter of 2013 was $51.7 million compared to $56.2 million in the prior-year period. Adjusted EBITDA from continuing operations were $191.9 million for the fourth quarter of 2013, compared to $193.0 million in the prior-year period.

Centaur revenue for the year ended December 31, 2013 was $1,758.9 million, up from the prior year by 1.2% on a constant currency basis. Our loss from continuing operations for the year ended December 31, 2013 was $555.4 million compared to $233.6 million in the prior-year period. Adjusted EBITDA from continuing operations were $717.1 million for the year ended December 31, 2013, compared to $735.8 million in the prior-year period.

On October 28, 2013, KCI closed on the previously-announced acquisition of Systagenix. Systagenix has a broad portfolio of innovative advanced wound care products with a focus on moist wound healing dressings - including PROMOGRAN PRISMA®, the collagen dressing market leader, TIELLE® (foam) and ADAPTIC® (non adherent contact layers). Systagenix distributes over 20 million advanced wound care dressings each month to more than 70 countries.

The successful completion of the Systagenix acquisition marks an important milestone in the advancement of our long-term strategy to be the global leader in transformational healing solutions. Over the coming quarters, we will continue integrating the Systagenix business into our broader wound care portfolio of products and therapies. As a result, we have renamed our business segments. Revenues related to KCI and Systagenix products are included within the Advanced Wound Therapeutics segment and revenue related to LifeCell is now reported under the Regenerative Medicine segment. We believe these segments reflect the nature of our businesses and are consistent with the manner in which we manage the Company.

“We are pleased with both the performance of our Regenerative Medicine business and the progress we continue to make in our Advanced Wound Therapeutics business,” said Joe Woody, President and Chief Executive Officer. 

Our consolidated financial statements include Systagenix results for the period subsequent to the close date of the acquisition.



The following information was filed by Acelity L.P. Inc. on Thursday, March 6, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Schedule Ii
Schedule Ii (details)
Consolidated Balance Sheets
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income (loss)
Consolidated Statements Of Comprehensive Income (loss) (parenthetical)
Consolidated Statements Of Equity
Consolidated Statements Of Equity (parenthetical)
Consolidated Statements Of Operations
Accounting For Goodwill And Other Non-current Assets
Accounting For Goodwill And Other Non-current Assets (tables)
Accounting For Goodwill And Other Non-current Assets Debt Issuance Costs (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Definite-lived And Indefinite-lived Intangible Assets (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Estimated Amortization Expense (details)
Accounting For Goodwill And Other Non-current Assets Schedule Of Goodwill (details)
Business Combination
Business Combination Business Acquisition, Pro Forma (details)
Business Combination Business Combination (tables)
Business Combination Other Acquisitions (details)
Commitments And Contingencies
Commitments And Contingencies (details)
Derivative Financial Instruments And Fair Value Measurements
Derivative Financial Instruments And Fair Value Measurements (tables)
Derivative Financial Instruments And Fair Value Measurements - Derivative Financial Instruments (details)
Derivative Financial Instruments And Fair Value Measurements - Fair Value And Balance Sheet Locations (details)
Derivative Financial Instruments And Fair Value Measurements - Gain (loss) On Derivatives (details)
Equity
Equity (details)
Guarantor Condensed Consolidating Financial Statements
Guarantor Condensed Consolidating Financial Statements (tables)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Balance Sheet (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Cash Flow (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Statement Of Operations And Comprehensive Income (loss) (details)
Incentive Compensation Plans
Incentive Compensation Plans - Equity-based Compensation Expense And 401(k) Recognized Costs (details)
Incentive Compensation Plans - Equity-based Plans (details)
Incentive Compensation Plans - Stock Option Plans (details)
Incentive Compensation Plans Incentive Compensation Plans (tables)
Income Taxes (benefit)
Income Taxes (benefit) (tables)
Income Taxes (benefit) - Reconciliation Of The Allowance For Uncertain Tax Positions (details)
Income Taxes (benefit) - Schedule Of Components Of Income Tax Expense (benefit) (details)
Income Taxes (benefit) - Schedule Of Deferred Tax Assets And Liabilities (details)
Income Taxes (benefit) - Schedule Of Effective Inome Tax Rate Reconciliation (details)
Income Taxes (benefit) - Schedule Of Income Before Income Tax, Domestic And Foreign (details)
Leasing Obligations
Leasing Obligations (tables)
Leasing Obligations - Narrative (details)
Leasing Obligations - Schedule Of Future Minimum Lease Payments (details)
Long-term Debt
Long-term Debt (details)
Long-term Debt (tables)
Other Comprehensive Income (loss)
Other Comprehensive Income (loss) (details)
Other Comprehensive Income (loss) (tables)
Quarterly Financial Data (unaudited)
Quarterly Financial Data (unaudited) (details)
Quarterly Financial Data (unaudited) (tables)
Related Party Transactions
Related Party Transactions (details)
Sale Of Therapeutic Support Systems Assets
Sale Of Therapeutic Support Systems Assets (details)
Sale Of Therapeutic Support Systems Assets (tables)
Segment And Geographic Information
Segment And Geographic Information (details)
Segment And Geographic Information (tables)
Segment And Geographic Information Information On Segment Assets (details)
Segment And Geographic Information Schedule Of Depreciation And Other Amortization (details)
Segment And Geographic Information Schedule Of Gross Capital Expenditures (details)
Segment And Geographic Information Schedule Of Information On The Geographical Location Of Select Financial Information (details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Summary Of Significant Accounting Policies - Schedule Of Concentrations Of Accounts Receivable (details)
Supplemental Balance Sheet Data
Supplemental Balance Sheet Data (tables)
Supplemental Balance Sheet Data - Accounts Receivable, Net (details)
Supplemental Balance Sheet Data - Accrued Expenses And Other (details)
Supplemental Balance Sheet Data - Inventories, Net (details)
Supplemental Balance Sheet Data - Net Property, Plant, And Equipment (details)
CIK: 1557939
Form Type: 10-K Annual Report
Accession Number: 0001557939-14-000013
Submitted to the SEC: Mon Mar 10 2014 5:30:52 PM EST
Accepted by the SEC: Mon Mar 10 2014
Period: Tuesday, December 31, 2013
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1557939/0001557939-14-000013.htm